CHMP positive for Kevzara (sarilumab) to treat polymyalgia rheumatica
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Kevzara
The marketing authorisation holder for this medicinal product is Sanofi Winthrop Industrie. The CHMP adopted a new indication as follows: Polymyalgia rheumatica; Kevzara is indicated for the treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who experience a relapse during corticosteroid taper.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.